BSV Boosts R&D with In-House Biologics, Expands Women's Health Portfolio

BSV, Bharat Serums and Vaccines Ltd, has created innovative biologic products internally, showcasing their impressive research and development skills. They have a diverse collection of branded products in women's health, fertility, critical care, and immunoglobulins.

Mankind Pharma announced that it has finalized the deal to purchase BSV for a total of Rs 13,768 crore. The company's announcement signifies a major advancement, positioning them as a top player in the Indian market for women's health and fertility drugs, as well as granting them access to other difficult-to-enter products in the critical care sector with established advanced R&D technology platforms, according to a statement from the drug maker.

"Today, we warmly welcome BSV's 2,500 plus members to Mankind family adding a new chapter to our exciting journey and setting the stage for accelerated growth," Mankind Pharma Vice-chairman and Managing Director Rajeev Juneja stated.

Sanjiv Navangul, MD & CEO of BSV, stated that being part of the Mankind Pharma family enhances BSV, making it larger, more robust, and improved.

"Together, we will now be able to ensure wider access of our specialised and indigenously developed complex treatments to millions of patients in India and across the globe. We will together unlock new possibilities, explore opportunities and maximize potential that will help achieve our priorities and business goals," he added.